Filter and sort through our extensive collection of AI tools to find exactly what you need.
Personal Genome Diagnostics (PGDx) is a leading provider of advanced genomic testing solutions focused on cancer diagnostics and personalized medicine. The company specializes in liquid biopsy and tissue-based genomic profiling to identify somatic mutations, copy number variations, and other genetic alterations associated with cancer. Their services enable healthcare providers to make data-driven treatment decisions by offering comprehensive reports that include actionable insights for targeted therapies, immunotherapies, and clinical trial matching. PGDx utilizes next-generation sequencing (NGS) technologies and proprietary bioinformatics algorithms to ensure high accuracy and clinical relevance. Target users include oncologists, hospitals, and research institutions seeking to improve patient outcomes through precision oncology. The platform supports various cancer types, including lung, breast, colorectal, and others, with a focus on delivering timely and reliable results to guide personalized treatment strategies.
Guardant Health is a precision oncology company that specializes in liquid biopsy tests for cancer detection and monitoring. Their advanced tests, such as Guardant360 and Guardant Reveal, analyze circulating tumor DNA from a blood sample to provide comprehensive genomic profiling. This non-invasive approach allows for early cancer detection, treatment selection, and monitoring of therapy response. By leveraging next-generation sequencing and artificial intelligence, Guardant Health delivers accurate and timely results, typically within 7-14 days. The tests are designed to overcome the limitations of traditional tissue biopsies, offering a safer and more convenient alternative. Used by oncologists worldwide, Guardant Health's solutions empower personalized cancer care, improve patient outcomes, and support clinical research. With a focus on innovation, the company continues to develop new assays to address various cancer types and stages, enhancing global healthcare through cutting-edge technology and evidence-based practices.
